Hypertrophic cardiomyopathy (HCM) is a genetic condition characterized by abnormal thickening of the heart muscle, which can lead to obstructed blood flow and cardiac complications. It accounts for an estimated global prevalence of 1 in 200 to 1 in 500 individuals. According to the hypertrophic cardiomyopathy pipeline analysis by Expert Market Research, there is a growing focus on novel drugs and targeted therapeutics, with the current pipeline including several advanced-stage candidates aimed at improving cardiac function and reducing symptoms. Increasing awareness, advancements in genetic testing, and rising R&D investments are expected to drive significant growth in hypertrophic cardiomyopathy therapeutic products over the coming years.
Major companies involved in the hypertrophic cardiomyopathy pipeline analysis include Edgewise Therapeutics, Inc., Bristol-Myers Squibb, and others.
Leading drugs currently in the pipeline include EDG-7500, TN-201, and others.
Expanding research on sarcomeric protein modulation, increased use of biomarker-driven trial designs, and a surge in orphan drug designations are key factors accelerating hypertrophic cardiomyopathy pipeline development.
The Hypertrophic Cardiomyopathy Pipeline Analysis Report by Expert Market Research gives comprehensive insights into hypertrophic cardiomyopathy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hypertrophic cardiomyopathy. The hypertrophic cardiomyopathy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hypertrophic cardiomyopathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hypertrophic cardiomyopathy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hypertrophic cardiomyopathy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by abnormal thickening of the heart muscle, primarily affecting the left ventricle. It often results from mutations in genes encoding sarcomeric proteins. This thickening can obstruct blood flow and impair the heart’s ability to pump efficiently, sometimes leading to arrhythmias or sudden cardiac death.
Hypertrophic cardiomyopathy treatment involves beta blockers, calcium channel blockers, antiarrhythmic agents, and septal reduction therapies. Newer options, like cardiac myosin inhibitors, target the disease’s root cause to improve functional capacity and symptoms. In April 2023, Bristol Myers Squibb’s CAMZYOS (mavacamten) received a positive CHMP opinion, supporting its approval in Europe as the first cardiac myosin inhibitor for symptomatic obstructive HCM, based on Phase 3 trial success.
A 2024 published review highlights data on the incidence of hypertrophic cardiomyopathy (HCM) and obstructive HCM (oHCM). In the United States, HCM incidence rose from 3.0 to 3.8 per 10,000 between 2013 and 2019. Obstructive HCM (oHCM) incidence in the United States declined from 2.1 to 1.5 per 10,000 during the same period. In the United Kingdom, about 1 in 500 individuals are affected.
This section of the report covers the analysis of hypertrophic cardiomyopathy drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total hypertrophic cardiomyopathy clinical trials, with 37.5%, showcasing strong clinical development and innovation. This is followed by phase III at 34.38%, reflecting a solid pipeline nearing regulatory submission. The remaining phases include phase I and phase IV at 12.5% each and early phase I at 3.13%. This progression indicates a robust pipeline, poised to drive advancements in hypertrophic cardiomyopathy treatment.
The drug molecule categories covered under the hypertrophic cardiomyopathy pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapies, RNA-based therapeutics, and others. The hypertrophic cardiomyopathy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hypertrophic cardiomyopathy.
Cardiac myosin inhibitors are emerging as a novel drug class for treating hypertrophic cardiomyopathy. For instance, aficamten, a next-in-class cardiac myosin inhibitor developed by Cytokinetics, is under regulatory review. In December 2024, the U.S. Food and Drug Administration accepted its New Drug Application for obstructive hypertrophic cardiomyopathy, with a target action date set for September 26, 2025.
The EMR report for the hypertrophic cardiomyopathy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hypertrophic cardiomyopathy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hypertrophic cardiomyopathy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hypertrophic cardiomyopathy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hypertrophic cardiomyopathy drug candidates.
TN-201 is a gene therapy drug sponsored by Tenaya Therapeutics. It is currently undergoing a Phase I/II clinical trial (MyPEAK-1) to assess its safety, tolerability, and pharmacodynamics in adults with symptomatic MYBPC3 mutation-associated hypertrophic cardiomyopathy (HCM). This recombinant AAV9 vector delivers the myosin binding protein C gene, aiming to address the disease at its genetic root.
EDG-7500 was developed by Edgewise Therapeutics, Inc. The drug candidate is currently in a Phase II trial, where it is being evaluated for its safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with hypertrophic cardiomyopathy. This oral, selective cardiac sarcomere modulator aims to improve cardiac function by targeting diastolic dysfunction in both obstructive and nonobstructive HCM patients.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hypertrophic Cardiomyopathy Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for hypertrophic cardiomyopathy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hypertrophic cardiomyopathy collaborations, regulatory environments, and potential growth opportunities.
Hypertrophic Cardiomyopathy Market Report and Forecast
North America Hypertrophic Cardiomyopathy Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share